Citations

Clear

3942 citation(s) found for "To, Van".

Runx1 is associated with breast cancer progression in MMTV‐PyMT transgenic mice and its depletion in vitro inhibits migration and invasion
Browne, Gillian , Taipaleenmäki, Hanna , Bishop, Nicole , Madasu, Sharath C. , Shaw, Leslie M., Wijnen, André J. van , Stein, Janet L. , Lian, Jane B. , van Wijnen, Andre J, Shaw, Leslie M., Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | March 20, 2015 | Volume: 230 | Issue: 10 | Pages: 2522-2532

10.1002/jcp.24989 | PMID 25802202 Get It

Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic abnormalities in Runx1 cause leukemia. Runx1 is functionally promiscuous and acts as either an oncogene or tumor suppressor gene in certain epithelial cancers. Recent evidence suggests that Runx1 is an important factor in breast cancer, however, its role remains ambiguous. Here, we addressed whether Runx1 has a specific pathological role during breast cancer progression and show that Runx1 has an oncogenic function. We observed elevated Runx1 expression in a subset of human breast cancers. Furthermore, throughout the course of disease progression in a classical mouse model of breast cancer (i.e., the MMTV‐PyMT transgenic model), Runx1 expression increases in the primary site (mammary gland) and is further upregulated in tumors and distal lung metastatic lesions. Ex vivo studies using tumor epithelial cells derived from these mice express significantly higher levels of Runx1 than normal mammary epithelial cells. The tumor cells exhibit increased rates of migration and invasion, indicative of an aggressive cancer phenotype. Inhibition of Runx1 expression using RNA interference significantly abrogates these cancer‐relevant phenotypic characteristics. Importantly, our data establish that Runx1 contributes to murine mammary tumor development and malignancy and potentially represents a key disease‐promoting and prognostic factor in human breast cancer progression and metastasis. J. Cell. Physiol. 230: 2522–2532, 2015. © 2015 Wiley Periodicals, Inc.
Patient characteristics associated with the level of patient‐reported care coordination among male patients with colorectal cancer in the Veterans Affairs health care system
Jackson, George L., Zullig, Leah L. , Provenzale, Dawn, Clauser, Steven B., Jindal, Rahul M. , Ryn, Michelle van , Phelan, Sean M. , Griffin, Joan M. , van Ryn, Michelle, Haggstrom, David Andrew , van Ryn, Michelle

Mayo Clinic

Cancer | March 17, 2015 | Volume: 121 | Issue: 13 | Pages: 2207-2213

10.1002/cncr.29341 | PMID 25782082 Get It

BACKGROUNDThe current study was performed to determine whether patient characteristics, including race/ethnicity, were associated with patient‐reported care coordination for patients with colorectal cancer (CRC) who were treated in the Veterans Affairs (VA) health care system, with the goal of better understanding potential goals of quality improvement efforts aimed at improving coordination.METHODSThe nationwide Cancer Care Assessment and Responsive Evaluation Studies survey involved VA patients with CRC who were diagnosed in 2008 (response rate, 67%). The survey included a 4‐item scale of patient‐reported frequency (“never,” “sometimes,” “usually,” and “always”) of care coordination activities (scale score range, 1‐4). Among 913 patients with CRC who provided information regarding care coordination, demographics, and symptoms, multivariable logistic regression was used to examine odds of patients reporting optimal care coordination.RESULTSVA patients with CRC were found to report high levels of care coordination (mean scale score, 3.50 [standard deviation, 0.61]). Approximately 85% of patients reported a high level of coordination, including the 43% reporting optimal/highest‐level coordination. There was no difference observed in the odds of reporting optimal coordination by race/ethnicity. Patients with early‐stage disease (odds ratio [OR], 0.60; 95% confidence interval [95% CI], 0.45‐0.81), greater pain (OR, 0.97 for a 1‐point increase in pain scale; 95% CI, 0.96‐0.99), and greater levels of depression (OR, 0.97 for a 1‐point increase in depression scale; 95% CI, 0.96‐0.99) were less likely to report optimal coordination.CONCLUSIONSPatients with CRC in the VA reported high levels of care coordination. Unlike what has been reported in settings outside the VA, there appears to be no racial/ethnic disparity in reported coordination. However, challenges remain in ensuring coordination of care for patients with less advanced disease and a high symptom burden. Cancer 2015;121:2207–2213. © 2015 American Cancer Society.
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Forero‐Torres, Andres , Varley, Katherine E. , Abramson, Vandana G. , Liu, Minetta C. , Nanda, Rita , Storniolo, Anna Maria , Poznak, Catherine Van , Nangia, Julie R. , Irvin, William , Santos, Jennifer F. De Los , Haluska, Paul , Grizzle, William E. , Myers, R , Wolff, Antonio C. , Li, Yufeng , Vaklavas, Christos , Lin, Nancy U. , Rugo, Hope S. , Traina, Tiffany A , Patil, Sujata N , Krontiras, Helen , Wolff, Antonio C , Abramson, Vandana G

Mayo Clinic

Clinical Cancer Research | March 16, 2015 | Volume: 21 | Issue: 12 | Pages: 2722-2729

10.1158/1078-0432.ccr-14-2780 | PMID 25779953 Get It

Abstract Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: Randomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required. Results: Among 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and 29%, respectively, with no grade 4–5. Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm. Conclusions: ORR and PFS were similar in both. Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents. ROCK pathway activation merits further evaluation. Clin Cancer Res; 21(12); 2722–9. ©2015 AACR. See related article by Paoletti et al., p. 2771
Rapid Pituitary Apoplexy Regression: What Is the Time Course of Clot Resolution?
Jackson, Devon L. , Van Gompel, Jamie J, Jackson, Devon , Gompel, Jamie J. Van

Mayo Clinic

Case Reports in Radiology | March 15, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-5

10.1155/2015/268974 | PMID 25861507 Get It

A 29-year-old male patient with a functioning pituitary macroadenoma is discussed. The pituitary mass was detected by MRI after the patient presented with sudden onset of headache, suggestive of an apoplectic event. The headache resolved with analgesic medications. Within a follow-up period of one week, the pituitary mass had spontaneously regressed to nearly half its original size without any therapy. The patient never reported any visual complaints and displayed no signs of hypopituitarism. Elevated prolactin levels were present. Seven weeks after the initial event, the pituitary mass showed continued regression on MRI. Prolactin levels remained elevated. This case provides a unique look at the rapid spontaneous regression of mass effect that may occur following apoplexy of a pituitary adenoma.
Continuous Age- and Sex-Adjusted Reference Intervals of Urinary Markers for Cerebral Creatine Deficiency Syndromes: A Novel Approach to the Definition of Reference Intervals
Mørkrid, Lars , Rowe, Alexander D. , Elgstøen, Katja Benedikte Prestø , Olesen, Jess Have, Ruijter, George J. G. , Tortorelli, Silvia , Kyriakopoulou, Lianna , Wamelink, Mirjam M. C. , Kamp, Jiddeke M. van de , Salomons, Gajja S. , Rinaldo, Piero, Hall, Patricia , Schulze, Andreas

Mayo Clinic

Clinical Chemistry | March 10, 2015 | Volume: 61 | Issue: 5 | Pages: 760-768

10.1373/clinchem.2014.235564 | PMID 25759465 Get It

Abstract BACKGROUND Urinary concentrations of creatine and guanidinoacetic acid divided by creatinine are informative markers for cerebral creatine deficiency syndromes (CDSs). The renal excretion of these substances varies substantially with age and sex, challenging the sensitivity and specificity of postanalytical interpretation. METHODS Results from 155 patients with CDS and 12 507 reference individuals were contributed by 5 diagnostic laboratories. They were binned into 104 adjacent age intervals and renormalized with Box–Cox transforms (Ξ). Estimates for central tendency (μ) and dispersion (σ) of Ξ were obtained for each bin. Polynomial regression analysis was used to establish the age dependence of both μ[log(age)] and σ[log(age)]. The regression residuals were then calculated as z-scores = {Ξ − μ[log(age)]}/σ[log(age)]. The process was iterated until all z-scores outside Tukey fences ±3.372 were identified and removed. Continuous percentile charts were then calculated and plotted by retransformation. RESULTS Statistically significant and biologically relevant subgroups of z-scores were identified. Significantly higher marker values were seen in females than males, necessitating separate reference intervals in both adolescents and adults. Comparison between our reconstructed reference percentiles and current standard age-matched reference intervals highlights an underlying risk of false-positive and false-negative events at certain ages. CONCLUSIONS Disease markers depending strongly on covariates such as age and sex require large numbers of reference individuals to establish peripheral percentiles with sufficient precision. This is feasible only through collaborative data sharing and the use of appropriate statistical methods. Broad application of this approach can be implemented through freely available Web-based software.
Impact of weight bias and stigma on quality of care and outcomes for patients with obesity
Yeazel, Mark W. , Hellerstedt, Wendy L., Ryn, Michelle van , Phelan, Sean M. , Burgess, Darren J. , Griffin, Joan M. , van Ryn, Michelle

Mayo Clinic

Obesity Reviews | March 5, 2015 | Volume: 16 | Issue: 4 | Pages: 319-326

10.1111/obr.12266 | PMID 25752756 Get It

Summary The objective of this study was to critically review the empirical evidence from all relevant disciplines regarding obesity stigma in order to (i) determine the implications of obesity stigma for healthcare providers and their patients with obesity and (ii) identify strategies to improve care for patients with obesity. We conducted a search of M edline and PsychInfo for all peer‐reviewed papers presenting original empirical data relevant to stigma, bias, discrimination, prejudice and medical care. We then performed a narrative review of the existing empirical evidence regarding the impact of obesity stigma and weight bias for healthcare quality and outcomes. Many healthcare providers hold strong negative attitudes and stereotypes about people with obesity. There is considerable evidence that such attitudes influence person‐perceptions, judgment, interpersonal behaviour and decision‐making. These attitudes may impact the care they provide. Experiences of or expectations for poor treatment may cause stress and avoidance of care, mistrust of doctors and poor adherence among patients with obesity. Stigma can reduce the quality of care for patients with obesity despite the best intentions of healthcare providers to provide high‐quality care. There are several potential intervention strategies that may reduce the impact of obesity stigma on quality of care.
Ragweed-induced expression of GATA-3, IL-4, and IL-5 by eosinophils in the lungs of allergic C57BL/6J mice
Justice, J. Paul, Borchers, Michael T. , Lee, Jamie J., Rowan, William H., Shibata, Yoshimi , Lee, J. J., Scott, Michael R. Van

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 3, 2015 | Volume: 282 | Issue: 2 | Pages: L302-L309

10.1152/ajplung.00158.2001 | PMID 11792635 Get It

Allergen-induced recruitment of T lymphocytes and eosinophils to the airways is associated with increased expression of the transcription factor GATA-3. In this study, the relationship between airway inflammation and GATA-3 expression in the lungs was investigated using ragweed-sensitized C57BL/6J mice. Intratracheal ragweed challenge increased both the number of GATA-3-expressing cells in the perivascular and peribronchial regions and the amount of expression per cell. Interleukin (IL)-4 and IL-5 levels in bronchoalveolar lavage fluid were upregulated in parallel with GATA-3 expression. GATA-3 mRNA and protein colocalized to eosinophils. Eosinophils isolated from the lungs and stimulated with phorbol 12-myristate 13-acetate and/or A-23187 released IL-5. The release was inhibited by actinomycin D, which indicates that de novo synthesis of the cytokine was involved. Western blot analysis of proteins from isolated eosinophils demonstrated expression of the p50 subunit of nuclear factor-κB, a transcription factor that is implicated in control of GATA-3 expression. These data provide evidence that allergen challenge increases GATA-3 and proinflammatory cytokine expression by pulmonary eosinophils, which could provide positive feedback for the inflammatory response.
Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardioprotection
Dzeja, Petras P. , Bast, Peter, Özcan, Cevher , Valverde, Arturo M. , Holmuhamedov, Ekhson , Wylen, David G. L. Van, Terzic, André

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | March 3, 2015 | Volume: 284 | Issue: 4 | Pages: H1048-H1056

10.1152/ajpheart.00847.2002 | PMID 12666660 Get It

Modulation of mitochondrial respiratory chain, dehydrogenase, and nucleotide-metabolizing enzyme activities is fundamental to cellular protection. Here, we demonstrate that the potassium channel opener diazoxide, within its cardioprotective concentration range, modulated the activity of flavin adenine dinucleotide-dependent succinate dehydrogenase with an IC50of 32 μM and reduced the rate of succinate-supported generation of reactive oxygen species (ROS) in heart mitochondria. 5-Hydroxydecanoic fatty acid circumvented diazoxide-inhibited succinate dehydrogenase-driven electron flow, indicating a metabolism-dependent supply of redox equivalents to the respiratory chain. In perfused rat hearts, diazoxide diminished the generation of malondialdehyde, a marker of oxidative stress, which, however, increased on diazoxide washout. This effect of diazoxide mimicked ischemic preconditioning and was associated with reduced oxidative damage on ischemia-reperfusion. Diazoxide reduced cellular and mitochondrial ATPase activities, along with nucleotide degradation, contributing to preservation of myocardial ATP levels during ischemia. Thus, by targeting nucleotide-requiring enzymes, particularly mitochondrial succinate dehydrogenase and cellular ATPases, diazoxide reduces ROS generation and nucleotide degradation, resulting in preservation of myocardial energetics under stress.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele, Angela, Yee, Douglas , Berry, Donald A. , Albain, Kathy S. , Benz, Christopher C. , Buxton, Meredith , Chia, Stephen , Chien, A. Jo , Clark, Amy S. , Edmiston, Kirsten K., Forero‐Torres, Andres , Haddad, Tufia C. , Haley, Barbara , Haluska, Paul , Korde, Larissa A. , Leyland‐Jones, Brian , Liu, Minetta C. , Melisko, Michelle , Minton, Susan, Moulder, Stacy L. , Nanda, Rita , Olopade, Olufunmilayo I. , Paoloni, Melissa, Park, John W., Parker, Barbara A. , Perlmutter, Jane , Petricoin, Emanuel F. , Symmans, Fraser, Tripathy, Debasish , Veer, Laura J. van’t , Viscusi, Rebecca K., Symmans, W. Fraser , Boughey, Judy, Boughey, Judy C. , Hui, Jane Yuet Ching , Elias, Anthony , Hylton, Nola M. , Isaacs, Claudine , Kaplan, Henry G. , Rugo, Hope S. , Wallace, Anne M. , Wolf, Denise M. , Yau, Christina , Esserman, Laura J. , Olopade, Olufunmilayo I , Symmans, W Fraser , Yee, Douglas

Mayo Clinic

Clinical Cancer Research | February 26, 2015 | Volume: 21 | Issue: 13 | Pages: 2911-2915

10.1158/1078-0432.ccr-14-1760 | PMID 25712686 Get It

AbstractThe many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach. Clin Cancer Res; 21(13); 2911–5. ©2015 AACR.
The role of families in decisions regarding cancer treatments
Hobbs, Gabriela , Landrum, Mary Beth , Arora, Neeraj K. , Ganz, Patricia A. , Ryn, Michelle van , Weeks, Jane C., Mack, Jennifer W. , Keating, Nancy L. , Hobbs, Gabriela S , van Ryn, Michelle

Mayo Clinic

Cancer | February 23, 2015 | Volume: 121 | Issue: 7 | Pages: 1079-1087

10.1002/cncr.29064 | PMID 25708952 Get It

BACKGROUNDShared decision‐making is an important component of patient‐centered care and is associated with improved outcomes. To the authors' knowledge, little is known concerning the extent and predictors of the involvement of a patient's family in decisions regarding cancer treatments.METHODSThe Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium is a large, multiregional, prospective cohort study of the cancer care and outcomes of patients with lung and colorectal cancer. Participants reported the roles of their families in decision‐making regarding treatment. Multinomial logistic regression was used to assess patient factors associated with family roles in decisions.RESULTSAmong 5284 patients, 80 (1.5%) reported family‐controlled decisions, with the highest adjusted rates (12.8%) noted among non‐English‐speaking Asians. Among the 5204 remaining patients, 49.4% reported equally sharing decisions with family, 22.1% reported some family input, and 28.5% reported little family input. In adjusted analyses, patients who were married, female, older, and insured more often reported equally shared decisions with family (all P <.001). Adjusted family involvement varied by race/ethnicity and language, with Chinese‐speaking Asian (59.8%) and Spanish‐speaking Hispanic (54.8%) patients equally sharing decisions with family more often than white individuals (47.6%). Veterans Affairs patients were least likely to report sharing decisions with family, even after adjustment for marital status and social support (P <.001).CONCLUSIONSThe majority of patients with newly diagnosed lung or colorectal cancer involve family members in treatment decisions. Non‐English‐speaking Asians and Hispanics rely significantly on family. Further studies are needed to determine the impact of family involvement in treatment decisions on outcomes; until then, physicians should consider eliciting patients' preferences for family involvement. Cancer 2015;121:1079–1087. © 2015 American Cancer Society.